Who is sponsoring SAFER-SCAD?

SAFER-SCAD is sponsored by Cardiology Research UBC.

What condition does SAFER-SCAD study?

SAFER-SCAD studies Coronary Artery Dissection, Spontaneous.

What drugs are being tested in SAFER-SCAD?

Interventions: ramipril, rosuvastatin, placebo.

What is the status of SAFER-SCAD?

SAFER-SCAD is currently TERMINATED.

Last reviewed 2024-03-13 · How we verify

The Effects of Statin and Angiotensin-converting Enzyme Inhibitor on Coronary Flow Reserve, indEx of Microcirculatory Resistance, and Symptoms in Patients With Spontaneous Coronary Artery Dissection (SAFER-SCAD) Study

NCT02008786 Phase 4 TERMINATED

An emerging cause of heart attack in young women is a dissection (or tear) in the coronary arteries. Many of these young women continue to have chest pain long after the tear has healed and this is thought to be due to problems with their small blood vessels of the heart (or microcirculation). We want to determine whether commonly used medications for coronary artery disease including statins (for cholesterol) and angiotensin-converting enzyme inhibitors (for blood pressure) reduce chest pain and improve small vessel function in these patients.

Details

Lead sponsor	Cardiology Research UBC
Phase	Phase 4
Status	TERMINATED
Enrolment	18
Start date	2014-06
Completion	2019-09-13

Conditions

Coronary Artery Dissection, Spontaneous

Interventions

ramipril
rosuvastatin
placebo

Primary outcomes

Angina frequency domain of the SAQ — 16 weeks after each intervention
Angina frequency domain of the SAQ, collected at baseline and after each intervention to assess angina frequency change over time. We hypothesize that mean SAQ will improve by at least 20 points in each treatment group compared to placebo.

Countries

Canada